DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Sunitinib Malate Market Forecast for Pancreatic Cancer in G7 Countries (U.S., Germany, France, U.K., Italy, Spain, Japan) - 2016 to 2017" report to their offering.
The sunitinib malate market for pancreatic cancer is projected to reach USD 76.7 million by 2021, at a CAGR of 13.9% from 2016 to 2021. The growing incidence of pancreatic cancer (especially pNET) and increasing adoption of sunitinib malate in patients with unrespectable, locally advanced, or metastatic pNET are the major factors driving the sunitinib malate market for pancreatic cancer in G7 Countries. The overall sunitinib malate market for pancreatic cancer in G7 countries is expected to witness double-digit growth in the coming years.
This report covers the sunitinib malate market for pancreatic cancer in G7 countries U.S., Germany, France, U.K., Italy, Spain, and Japan. The U.S. is expected to be the largest market for sunitinib malate (for pancreatic cancer) primarily due to the higher number of patients suffering from pancreatic cancer in the country. However, the market in the U.K. is expected to witness a higher growth rate during the forecast period.
Countries Covered:
- U.S.
- Japan
- Germany
- France
- U.K.
- Italy
- Spain
Report Structure:
1.1 Disease Overview
1.2 Clinical Staging
1.3 Product Profile
1.4 Facts and Assumptions
1.5 Terminology
1.6 U.S.: Sutent Market for Pancreatic Cancer, 2010-2021
1.7 Germany: Sutent Market for Pancreatic Cancer, 2010-2021
1.8 France: Sutent Market for Pancreatic Cancer, 2010-2021
1.9 U.K.: Sutent Market for Pancreatic Cancer, 2010-2021
1.10 Italy: Sutent Market for Pancreatic Cancer, 2010-2021
1.11 Spain: Sutent Market for Pancreatic Cancer, 2010-2021
1.12 Japan: Sutent Market for Pancreatic Cancer, 2010-2021
1.13 View
1.14 Sources
For more information visit http://www.researchandmarkets.com/research/fhczcv/sunitinib_malate
